• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Five Top Papers From 2014 That Will Impact Your Practice

Slideshow

New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.

The best publications in a given year may be chosen because they are cited frequently, possibly because they warrant erudite editorials or because they are the most scientifically respected manuscripts. The road I’ve taken, however, is to select papers with results and/or conclusions that affect primary care practice-right now and for the immediate future.The references encompass situations and diseases that have frequently challenged me and are seen frequently in primary care:  - Hepatitis C  - Type 2 diabetes  - Insomnia  - Stroke  - Anticoagulation 

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

©vinnstock/Shutterstock.com

Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents

Grace Halsey
November 20th 2024
Article

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 14th 2024
Article

Your daily dose of the clinical news you may have missed.

STI Epidemic in US Shows Signs of Slowing, According to New CDC Report / STI test Image credit: ©syhin_stas/AdobeStock

STI Epidemic in US Shows Signs of Slowing, According to New CDC Report

Sydney Jennings
November 13th 2024
Article

More than 2.4 million STIs were reported in the US in 2023 — a 1.8% decrease from 2022, according to the CDC's annual STI report.

© 2024 MJH Life Sciences

All rights reserved.